
Opinion|Videos|August 19, 2024
Patient Access Advocacy for BTK Inhibitors
A panel of specialists discuss patient access advocacy for BTK inhibitors.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?
- What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































